AKESOBIO AUSTRALIA PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

Phase 2

Conditions: Atopic Dermatitis

Interventions: Drug: Placebo
Drug: AK120

First Posted Date: 2021-09-17

Last Posted Date: 2022-07-07

Lead Sponsor: Akesobio Australia Pty Ltd

Target Recruit Count: 105

Registration Number: NCT05048056

Locations: 🇺🇸
AkesoBio Investigative Site 2013, Spartanburg, South Carolina, United States
🇦🇺
AkesoBio Investigative Site 3003, Sydney, New South Wales, Australia
🇺🇸
AkesoBio Investigative Site 2003, Little Rock, Arkansas, United States

and more 20 locations

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

Early Phase 1

Active, not recruiting

Conditions: Advanced or Metastatic Solid Tumours

Interventions: Drug: AK127
Drug: AK104

First Posted Date: 2021-08-25

Last Posted Date: 2024-11-25

Lead Sponsor: Akesobio Australia Pty Ltd

Target Recruit Count: 66

Registration Number: NCT05021120

Locations: 🇦🇺
Ashford Cancer Centre Research, Adelaide, Australia
🇦🇺
Austin Health, Melbourne, Australia
🇦🇺
Monash Health, Melbourne, Australia

and more 2 locations

A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects

Phase 1

Completed

Conditions: Coronavirus Disease 2019 (COVID-19)

Interventions: Drug: AK119
Drug: Placebo

First Posted Date: 2020-08-18

Last Posted Date: 2021-10-18

Lead Sponsor: Akesobio Australia Pty Ltd

Target Recruit Count: 29

Registration Number: NCT04516564

Locations: 🇳🇿
Christchurch Clinical Studies Trust, Christchurch, New Zealand

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104

Phase 1

Completed

Conditions: Neoplasms Malignant

Interventions: Drug: AK117
Drug: AK117+AK104

First Posted Date: 2020-04-16

Last Posted Date: 2024-08-21

Lead Sponsor: Akesobio Australia Pty Ltd

Target Recruit Count: 38

Registration Number: NCT04349969

Locations: 🇦🇺
Blacktown Hospital, Sydney, New South Wales, Australia
🇦🇺
ICON Cancer Foundation, South Brisbane, Queensland, Australia
🇦🇺
Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia

and more 1 locations

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: AK120 or placebo- Part 2- Cohort 4
Drug: AK120 or placebo- Part 1- Cohort 5
Drug: AK120 or placebo- Part 1- Cohort 1
Drug: AK120 or placebo- Part 2- Cohort 1
Drug: AK120 or placebo- Part 2- Cohort 2
Drug: AK120 or placebo- Part 1- Cohort 4
Drug: AK120 or placebo- Part 1- Cohort 2
Drug: AK120 or placebo- Part 1- Cohort 3
Drug: AK120 or placebo- Part 2- Cohort 3

First Posted Date: 2020-02-05

Last Posted Date: 2022-08-17

Lead Sponsor: Akesobio Australia Pty Ltd

Target Recruit Count: 80

Registration Number: NCT04256174

Locations: 🇳🇿
P3 Research Tauranga, Tauranga, New Zealand
🇦🇺
CMAX Clinical Research, Adelaide, Australia
🇦🇺
Sinclair Dermatology, East Melbourne, Australia

and more 10 locations

A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Neoplasms Malignant

Interventions: Drug: AK112

First Posted Date: 2019-08-06

Last Posted Date: 2022-10-28

Lead Sponsor: Akesobio Australia Pty Ltd

Target Recruit Count: 151

Registration Number: NCT04047290

Locations: 🇦🇺
Blacktown Hospital, Sydney, New South Wales, Australia
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺
ICON Cancer Foundation, South Brisbane, Queensland, Australia

and more 4 locations

A Study of AK111 in Healthy Subjects

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: AK111 or Placebo

First Posted Date: 2018-08-09

Last Posted Date: 2020-09-21

Lead Sponsor: Akesobio Australia Pty Ltd

Target Recruit Count: 68

Registration Number: NCT03622021

Locations: 🇳🇿
Christchurch Clinical Studies Trust (CCST), Christchurch, New Zealand

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Cancer

Interventions: Biological: AK-105

First Posted Date: 2017-11-24

Last Posted Date: 2022-10-21

Lead Sponsor: Akesobio Australia Pty Ltd

Target Recruit Count: 108

Registration Number: NCT03352531

Locations: 🇦🇺
St Vincent's Hospital, Sydney (The Kinghorn Cancer Centre), Darlinghurst, New South Wales, Australia
🇦🇺
Border Medical Oncology, East Albury, New South Wales, Australia
🇦🇺
ICON Cancer Foundation, South Brisbane, Queensland, Australia

and more 2 locations

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors

Phase 1

Conditions: Advanced Cancer

Interventions: Biological: AK-104

First Posted Date: 2017-08-24

Last Posted Date: 2018-03-09

Lead Sponsor: Akesobio Australia Pty Ltd

Target Recruit Count: 153

Registration Number: NCT03261011

Locations: 🇦🇺
Linear Clinical Research/Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇦🇺
Austin Health, Heidelberg, Victoria, Australia
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

and more 1 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy